EXPLORE THE SCIENCE
TL;DR: A 2026 review in International Journal of Molecular Medicine mapped how exercise and fluoxetine overlap in Alzheimer’s disease mechanisms such as mitochondrial quality control, oxidative stress, inflammation, and neuroplasticity, but clinical combinatio…
Read article
TL;DR: A 2026 systematic review and meta-analysis in Bipolar Disorders found that poor medication adherence in bipolar disorder was linked to substance use, psychotic features, lower insight, poorer functioning, and several markers of more severe illness, but…
Read article
TL;DR: A 2026 systematic review and meta-analysis in Brain, Behavior, & Immunity – Health found that adding celecoxib to antidepressants was linked to lower depressive symptom scores in 7 small trials, but the efficacy evidence was rated very low certainty. Ke…
Read article
TL;DR: A 2026 secondary analysis in Addiction found that adults switched to very-low-nicotine cigarettes often used alternative nicotine products and maintained much higher nicotine intake than cigarette-only users. Key Findings 438 smokers: The parent randomi…
Read article
TL;DR: A 2026 systematic review in Future Science OA found early medication evidence for online behavioral addictions, but the 20 included studies were mostly small, male-heavy, and short-term. Key Findings Medication evidence stayed early: The review found sm…
Read article
TL;DR: A 2026 real-world study in Journal of Clinical Sleep Medicine found that glucagon-like peptide-1 receptor agonist use was associated with lower 3-year cardiovascular-event risk in adults with obesity and obstructive sleep apnea. Key Findings 18,523 matc…
Read article
TL;DR: A 2026 review in International Journal of Nanomedicine argued that depression nanomedicine should move beyond blood-brain-barrier delivery alone and be judged by target engagement, neuroimmune-barrier-plasticity effects, safety, manufacturability, and p…
Read article
TL;DR: A 2026 study in European Archives of Psychiatry and Clinical Neuroscience linked sustained quetiapine treatment with better high-working-memory cognitive performance in schizophrenia spectrum disorder, but the genetic tests did not support the proposed…
Read article
TL;DR: A 2026 real-world cohort study in The Journal of Prevention of Alzheimer’s Disease found that lecanemab-treated Alzheimer’s patients had lower Neuropsychiatric Inventory scores over follow-up, and 6-month symptom reductions were associated with regional…
Read article
TL;DR: A 2026 case study in Biomedical Reports described a 28-year-old woman with bipolar II disorder whose stable subclinical counting compulsion worsened and expanded into new obsessive-compulsive symptoms within 3 days of starting cariprazine, then returned…
Read article